Therapeutic Plasma Exchange Market Report 2026

The therapeutic plasma exchange market size has grown strongly in recent years. It will grow from $1.61 billion in 2025 to $1.76 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased diagnosis of autoimmune disorders, expansion of hospital transfusion services, availability of centrifugation-based technologies, growing clinician familiarity with apheresis procedures, adoption of standardized treatment protocols.

The therapeutic plasma exchange market size is expected to see strong growth in the next few years. It will grow to $2.4 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing demand for advanced autoimmune therapies, increasing adoption of membrane separation technology, expansion of outpatient apheresis services, rising investment in blood purification technologies, higher focus on personalized immunological treatments. Major trends in the forecast period include increasing adoption of automated plasma exchange systems, rising use of tpe in neurological disorders, growing demand for high-efficiency separation technologies, expansion of hospital-based apheresis units, enhanced focus on treatment safety and monitoring.

The high prevalence of hematological disorders is expected to drive growth in the therapeutic plasma exchange market in the coming years. Hematological disorders, or blood disorders, are medical conditions that affect the blood and blood-forming tissues, including the bone marrow, lymph nodes, and spleen. These disorders are increasing due to genetic predispositions, environmental factors, and lifestyle changes. Therapeutic plasma exchange (TPE) is used in hematological disorders to remove harmful substances from the plasma, such as autoantibodies in autoimmune hemolytic anemia or immune complexes in thrombotic thrombocytopenic purpura, thereby reducing disease severity and improving patient outcomes. For example, in July 2024, Cancer Research UK, a UK-based charity, reported that the average number of new Hodgkin lymphoma cases per year in the UK is expected to rise from approximately 2,400 cases in 2023-2025 to around 2,900 cases in 2038-2040. Therefore, the high prevalence of hematological disorders is fueling growth in the therapeutic plasma exchange market.

Key companies in the therapeutic plasma exchange market are focusing on advancing automation, enhancing device safety, and improving system efficiency to drive clinical adoption and streamline workflows. Automation involves using technology to perform tasks automatically without constant human intervention. For instance, in November 2024, Terumo BCT, a US-based medical device company, launched software update V12.1 for its Spectra Optia Apheresis System, improving usability, strengthening cybersecurity, and optimizing workflow, including automatic pump pause during single-needle exchange and alarm mitigation. The system supports therapeutic plasma exchange with a mean plasma removal efficiency of 87%, minimal extracorporeal volume (141 mL), and a median platelet loss of just 1%. These advancements in automation and device safety are increasing TPE adoption in hospitals and specialty clinics; however, high capital costs and the need for trained personnel continue to limit use in resource-constrained settings.

In October 2025, Accord Plasma B.V., a Netherlands-based provider of plasma-derived medicines and large-scale plasma fractionation services, acquired Prothya Biosolutions Belgium BV for an undisclosed amount. Through this acquisition, Accord Plasma aims to strengthen its global plasma therapy capabilities by integrating Prothya’s European expertise to expand production capacity and improve access to essential plasma-derived medicines across multiple regions. Prothya Biosolutions, based in Belgium, specializes in plasma fractionation services and operates major manufacturing facilities and plasma collection centers that supply critical plasma-derived therapies.

Major companies operating in the therapeutic plasma exchange market are Medica S.p.A., Fresenius SE and Co. KGaA, Medtronic Plc., Asahi Kasei Corporation, Toray Industries Inc., Baxter International Inc., B Braun Melsungen AG, Terumo Corporation, Kaneka Corporation, Octapharma AG, Haemonetics Corporation, Miltenyi Biotec Technology And Trading Co. Ltd., Macopharma SA, Cerus Corporation, Apellis Pharmaceuticals Inc., ImmunoTek Bio Centers LLC, CytoSorbents Corporation, Kawasumi Laboratories America Inc.

North America was the largest region in the therapeutic plasma exchange market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the therapeutic plasma exchange market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic plasma exchange market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the therapeutic plasma exchange market by increasing costs of imported centrifugation systems, membrane filters, disposable kits, and monitoring equipment. Hospitals and blood collection centers in North America and Europe are most affected due to reliance on imported apheresis consumables, while Asia-Pacific faces cost pressures on device manufacturing. These tariffs are increasing procedural costs and procurement complexity. However, they are also driving domestic production of consumables, local assembly of apheresis devices, and innovation in reusable and cost-efficient plasma exchange technologies.

The therapeutic plasma exchange market research report is one of a series of new reports that provides therapeutic plasma exchange market statistics, including therapeutic plasma exchange industry global market size, regional shares, competitors with a therapeutic plasma exchange market share, detailed therapeutic plasma exchange market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic plasma exchange industry. This therapeutic plasma exchange market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Therapeutic plasma exchange (TPE) is a medical procedure used to treat certain autoimmune and other conditions. In TPE, blood is drawn from the body, plasma - the liquid component - is separated from the blood cells, and the blood cells are then returned to the body, often combined with a replacement fluid. This process helps remove harmful substances from the blood, such as autoantibodies or toxins, which can contribute to various diseases.

The main types of therapeutic plasma exchange include therapeutic plasma exchange (TPE) and double-filtered plasmapheresis (DFPP). TPE involves removing plasma from the blood and replacing it with a replacement fluid to eliminate harmful substances or excess components. It is used for several conditions, including neurological disorders, hematological disorders, renal disorders, metabolic disorders, and others. Technologies employed include centrifugation and membrane separation, and the procedure is utilized by end-users such as blood collection centers, hospitals and clinics, transfusion centers, and others.

The therapeutic plasma exchange market consists of revenues earned by entities by providing services such as patient evaluation, treatment planning, medical monitoring, and plasma separation. The market value includes the value of related goods sold by the service provider or included within the service offering. The therapeutic plasma exchange market also includes the sale of plasma separators, replacement fluids, anticoagulants, catheters and access devices, disposable consumables, and monitoring equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.